1

Audrey’s Life Science Meeting Picks for May 2014 - June 2014

Complimentary Service of AudreysNetwork.com May 18, 2014

************************************************************ BioCentury This Week, See new program Webcast Starting Sunday, May 18, 2014, www.biocenturytv.com, Available anytime starting at 9:00 a.m. EDT

Date: Original broadcast Sunday, Starts May 18, 2014

Watch the Broadcast 8:30 - 9:00 a.m. EDT

WUSA Channel 9 in Washington, D.C.

Watch on the Web Any Time www.biocenturytv.com

Continuously available starting at 9:00 a.m.

Topic: “Telehealth: The Future of Medicine” Topic Description

Healthcare — Just a Click Away -Telehealth could replace doctor office visits with in-home, online check-ups to monitor patients and diagnose some of the most complex diseases — especially patients in rural areas. It could also reduce costly ER and specialist visits and improve patient compliance with their treatment regimens.

But licensing requirements and reimbursement are preventing Telehealth from going viral. What is needed to make telemedicine available for all Americans? What challenges and limitations does telemedicine present?

In the latest edition, BioCentury This Week television puts Telehealth under the microscope with: • Former Sen. Tom Daschle, senior policy advisor at law firm DLA Piper • Dr. Ray Dorsey, professor of neurology and co-director of the Center For Human

Experimental Therapeutics at the University of Rochester Medical Center • John Jesser, VP and general manager of LiveHealth Online at WellPoint **********************************************************************

Bio2Device Group, Tuesday Morning, May 20, 2014 Topic: “Creating a Winning Life Science Product Marketing Plan” Speaker: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates, Blogger at

www.AudreysNetwork.com Date and Time: Tuesday, May 20, 2014, 8:30 am Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA Cost: No fee and no need to register for morning meetings

Topic Description The presentation will provide a roadmap for achieving a successful product marketing plan for life science industry products. The talk will cover the process and development of a strategy, positioning and tactics for marketing a life science product to its best advantage

and achieving the desired revenues and profit. Speaker Bio Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and Audreysnetwork.com is a life-

science business development and marketing consultant serving emerging biotech companies, an industry educator, and organization leader who teaches bioscience business

2

development and marketing courses at UC Berkeley Extension. She has more than 25 years of corporate managerial experience in the biopharmaceutical industry including Executive VP and Co-founder of Kowa Research Institute and U.S. and international management positions at Syntex Corporation (acquired by Roche) in market research, product

management, strategic marketing, and business development with a special emphasis on Europe and Asia/Pacific/Canada. ********************************************************************** SecureDocs.com, Tuesday Morning, May 20, 2014

Topic: “Free webinar--Startup Growth Series: Corporate Lawyers- When, Why, & How Much?” Speaker: Evan Pickering, Seed Mackall LLP Date and Time: Tuesday, May 20th, 10 AM PDT

Cost: Free Register to learn at http://info.securedocs.com/securedocs-webinar-registration-corporate-lawyer

Description of Complimentary Webinar Startups and small businesses benefit immensely from good legal advice during their infancy and growth phase. But deciding when to hire a lawyer and which lawyer to hire can

be daunting experience. This webinar will help you determine when to consult a lawyer by discussing the value a good lawyer can add to your business. You will also learn the difference between lawyers and which lawyer is right for you.

How to recognize that your business needs a corporate lawyer The value a corporate lawyer can add to your business How to choose the right lawyer Speaker Bio

Evan Mackall is an associate at Seed Mackall LLP and his practice encompasses a range of corporate matters, including venture capital, securities law, debt, mergers and acquisitions, and corporate governance. Prior to joining Seed Mackall, Mr. Pickering worked in the corporate departments of both O'Melveny & Myers LLP and Arnold & Porter LLP in San

Francisco. He received his J.D. from University of Michigan Law School. ********************************************************************** Janssen, Tuesday Mid-Day, May 20, 2014

Topic: “From the Trenches: Are you Ready to IPO?” Speakers: Carin Canale-Theakston | President and Founder, Canale Communications Inc. ; Bryan Giraudo | Managing Director, Leerink; John Orwin | President and Chief Executive

Officer, Relypsa Inc. Date and Time: Tuesday, May 20, 2014, 11:00 am – 1:30 pm Agenda 11:00 AM | Registration, Lunch, and Networking

11:30 AM | Presentation and Q&A 1:30 PM | Program Close Fees General Public | $35; Academic/Student Rate | $20

Location: Genentech Hall, Room N114 (GEN-N114), 600 16th Street, San Francisco, CA 94158

3

Register at http://www.eventbrite.com/e/from-the-trenches-are-you-ready-to-ipo-tickets-11053257591?aff=blast Program Overview

2013 was the year of the IPO for the biotech community with over 40 biotech companies going public. Biotech companies are continuing to be the toast of Wall Street in 2014 and as most soar above their IPO price, there appears to be no end in sight. But, even in this seemingly wide open window, not all life science companies should or could go public. If a potential IPO is on your radar screen, join us for an honest and transparent roundtable

discussion about lessons learned and key insights from those who have recently traveled the road to IPO. Discussions points include: Am I ready to go public?

What are the most critical questions to ask on the road to IPO? How long will the window hold? What's life like after going public? The "How to... Workshop" series is dedicated to giving you the keys to a successful

business, from creation to exit. As with all our events, the "How to... Workshop" is interactive and informal so bring your questions with you! Speaker Bio

Carin Canale-Theakston Carin Canale-Theakston | President and Founder, Canale Communications Inc. In her role as president, Carin works closely with client teams, having provided senior level strategy to more than 125 life science companies of all shapes and sizes ranging from pre-

series A financing to billion dollar public companies. In addition to client services, Carin is actively involved in the life science community. She is currently the vice chairwoman of the board of directors for BIOCOM, and a member of the board of directors for the San Diego Venture Group. Prior to founding Canale Communications, Carin was president of the life sciences division of international public relations firm Porter Novelli. Carin joined Porter

Novelli when the firm acquired boutique life sciences communication firm, Atkins + Associates, in which Carin was partner and managing director. Carin also held various positions for several agencies including Townsend Inc., Littlefield Communication and Burson-Marstellar. Read More»

***************************************************************** WIB-San Francisco, Tuesday Evening, May 20, 2014 Topic: Path to Market

Date and Time: 05/20/2014 - 6:00pm Location: Genomic Health, Redwood City Cost: Member-$30; nonmember-$60

Topic Description (Executive Director of Strategic Information Management at Celgene Corporation) in discussing the key areas involved in bringing your product to market. This presentation is the third installment of WIB’s Entrepreneurial Series and will discuss this critical time frame

in the lifecycle of a product. The experts will focus on strategic planning, product development, marketing and reimbursement of diagnostic products. Learn from the experts about some of the issues you need to be identifying and addressing at this stage in the product development process to ensure a smoother path to market.

Speaker Biographies

4

Lissa Goldenstein is a seasoned senior executive with over 30 years of leadership experience in bringing new products to market, predominately in the life science industry. She is a co-founder of Auxogyn and serves as its President, CEO, and Board Director. Prior to joining Auxogyn, Lissa served as President and CEO of Artemis Health, Inc. (now Verinata

Health, Inc.), a venture-backed company focused on developing non-invasive prenatal diagnostic tests. At Artemis Health, Lissa defined the company’s business strategy, broadened its product and intellectual property portfolio, and secured more than $20 million in funding over a three year period. Prior to joining Artemis Health, Lissa served as President and CEO of Argonaut Technologies, Inc. (NASDAQ: AGNT) from 2001 to 2005, at

which time Argonaut's assets were sold to Biotage, AB. Lissa received her B.S. in Architectural Engineering from Pennsylvania State University and her Professional Engineers license as a structural engineer in the State of California. Deborah Kilpatrick, Ph.D. joined CardioDx in 2006 as Vice President, Market Development,

assuming responsibility for building the company’s marketing and reimbursement capabilities. Dr. Kilpatrick oversees CardioDx’s commercial functions, including provider marketing and sales, managed care marketing and sales, market access, and public relations. Prior to joining CardioDx, she spent nine years at the Vascular Intervention

Division of Guidant Corporation, where her roles included Research Fellow, Director of Research and Technology Development, and Director of New Ventures. Dr. Kilpatrick also serves on the Advisory Boards for the Georgia Institute of Technology and its College of Engineering. She is on the Board of Directors for the Dystonia Medical Research Foundation,

and is a Fellow of the American Institute of Medical and Biological Engineering. Dr. Kilpatrick is a founder of the annual MedtechVision Conference in Silicon Valley, and has received a Rising Star award from the Healthcare Businesswoman's Association. She holds multiple U.S. patents, and a Ph.D. in mechanical engineering with a focus in cardiovascular

bioengineering from the Georgia Institute of Technology. Maureen Cronin, Ph.D. is an internationally recognized biotechnology industry executive, with expertise in, and passion for applied and translational science. She has over 20 years of R&D experience in biotechnology companies focused on applying cutting-edge technology to clinical diagnostics. Currently, Dr. Cronin serves as Executive Director of Strategic

Information Management at Celgene Corporation. In this role, she works directly with the Research and Early Development senior leadership to focus on creating the computational environment necessary to conduct drug development as a data and knowledge driven enterprise. Previously, Dr. Cronin has served as Sr. VP of Research and Product

Development at Foundation Medicine, and as Vice President of Translational Research at Genomic Health. Her expertise includes identifying optimal platform technologies and laboratory processes, assay integration and automation, data management, bioinformatics, and biostatistical analyses. Dr. Cronin’s Ph.D. is in Molecular Pharmacology from the

University of California, San Diego, and her undergraduate education from the University of California, Davis. Elaine Cheung is on the Business Development team at Illumina, the leading provider of next generation sequencing technologies. She focuses on strategies and deals to develop

molecular diagnostic business in NIPT, transplantation, and particularly in oncology. Previously, Elaine spent six years leading business development efforts at Genomic Health, where she led partnering efforts related to the company’s pipeline, international expansion, collaborations with pharma, and M&A diligence. Elaine began her career at VaxGen and

AVAcore technologies. She earned a B.S. in Biological Sciences and an M.S. in Management Science and Engineering, both from Stanford University, where she was also a Mayfield Fund Fellow. **************************************************************

HBA, Thursday Evening, May 22, 2014

5

Topic: “Competency-Based Interviewing”

Date and Time: Thursday, May 22, 2014: 5:30 PM - 8:00 PM Agenda

5:30 PM ‐ 6:00 PM Registra=on and networking

6:00 PM ‐ 6:15 PM Welcome/introductory remarks 6:30 PM ‐ 7:15 PM Panel discussion 7:15 PM ‐ 7:30 PM Q&A 7:30 PM ‐ 8:00 PM Closing and evalua=on/feedback

Location: The Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158 Cost Regular Late Member $35 $40 Non member $45 $52

Student $20 $25 Topic Description

HBA San Francisco presents a skill building event on competency‐based Interviewing in collabora=on with the Gladstone Ins=tutes and UCSF WILS. This event provides you with an opportunity to learn and discuss the experiences of senior level professionals from various life science companies and what their thoughts are on types of interview ques=ons asked, how to master answering these types of ques=ons and how to successfully land the job that you want by acing the interview.

The event will take place in a panel based format where each of the panelists will share their experiences. The panel comprises of Joni FauceL from the commercial training and development division at Genentech, Marco Rosa, an execu=ve career coach at Simplified Coach, Jennifer Troia, execu=ve director of HR at Sunesis Pharmaceu=cals and Donna

Dambach, director of small molecule and inves=ga=ve toxicology at Genentech. Learning objec9ves 1. Become acquainted with the concept of Competency‐Based interviewing 2. How to prepare effec=vely for a Competency‐Based interview in a life science company 3. How to master these techniques during the interview day that will lead to successful hiring For more program details and registra9on: bit.ly/1lQPbvg Join us for an evening with a panel of distinguished guests sharing their insight on how to master Ccmpetency-based interviewing techniques.

Event details HBA San Francisco presents a skill building event on competency-based Interviewing in collaboration with the Gladstone Institutes and UCSF WILS. This event provides you with an opportunity to learn and discuss the experiences of senior level professionals from various life science companies and what their thoughts are on types of interview questions asked, how to master answering these types of questions and how to successfully land the job that you want by acing the interview. The event will take place in a panel based format where each of the panelists will share their experiences. The panel comprises of Joni Faucett from the commercial training and development division at Genentech, Marco Rosa, an executive career coach at Simplified Coach, Jennifer Troia, executive director of HR at Sunesis Pharmaceuticals and Donna Dumbach, director of small molecule and investigative toxicology at Genentech.

************************************************************ CABS, Friday Afternoon, May 23, 2014 Event: “CABS Science and Technology Workshop - Large Molecule Drug Discovery and Development Series - Biologics CMC Development and Regulatory Considerations”

6

Speakers and topics: Esohe Idusogie, Senior Director, Analytical and Process Development, OncoMed Pharmaceuticals; Talk title: The path to IND: product characterization, stability and challenges along the way; Krishna Allamneni, Director, Preclinical Development at NGM Biopharmaceuticalsm Talk title: TBD (she will focus on Toxicology issues related to CMC

development); Vinaya Kapoor, Director, Global Regulatory Affairs CMC, Johnson & Johnson, Talk title: Biologics CMC Development: Regulatory Considerations and Global Perspectives Date and Time: 2014-5-23 Friday, 12:00 pm to 4:00 pm Location: Embassy Suites, 250 Gateway Blvd, South San Francisco, CA 94080 Cost: Lunch will be provided.

Online (by May 20th, with lunch): Active CABS member: $25; Non-member: $40 Onsite (lunch is not guaranteed): $40 Please visit www.cabsweb.org for registration details. Event Description As a continuation of "Large Molecule Drug Development" series, this workshop will focus on preclinical development of biologics and regulatory requirement for CMC development in US/EU and China. Many CMC concerns regarding biological drugs are different from small

molecule drugs. The regulatory environment of biological drugs is more dynamic as well. Industry leaders will provide comprehensive overview and case studies to illustrate the challenges and success of their work and its applications to further our understanding of biologic drug development.

Speaker Bios Esohe Idusogieis the Senior Director at OncoMed Pharmaceuticals. She hasbeen leading the Analytical/BioAnalytical Groupinprocessdevelopment atOncoMedand has contributed significantly to the successful IND filing of clinical candidates since2007. Prior to this, Esohe was at Abgenix/Amgenwheresheassumedaleadershipposition in theprocessdevelopment group,supportinganalytical methodsdevelopment,assay andproductcomparabilitystudies,validation,andtechnologytransfer. EsohereceivedherPhDinBiochemistryin1997 fromtheUniversityof NotreDame,NotreDame, IN. Shecompleted herpostdoctoral fellowship atGenentech. Vinaya Kapoor is a Director of Global Regulatory Affairs - CMC at Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson. Vinaya's CMC regulatory experiences include small molecules and biologics in clinical development phase, pre-approval and post-approval activities for US and global registrations. Prior to working in regulatory affairs, Vinaya worked in pharmaceutical development at Merck & Co. Vinaya has a Ph.D in Chemical Engineering from the University of Notre Dame, USA and B. Tech in Chemical Engineering from the Indian Institute of Technology, Bombay. ********************************************************************** Bio2Device Group, Tuesday Morning, May 27, 2014

Topic: “Breastfeeding Support using Google Glass” Speaker: Madeline Sands, Leader of the Breastfeeding Support Project, and Elloise Foster, Marketing and Account Manager, Small World Social Date and Time: Tuesday, May 27, 2014, 8:30 am Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA Cost: No fee and no need to register for morning meetings Topic Description

7

Wearable technologies can provide exciting new opportunities across health and science, but what types of problems can these new technologies help solve? This interactive session will outline a recent trial conducted in Australia, which like many countries around the world, is not meeting the World Health Organization’s minimum breastfeeding target rates.

Breastfeeding is one of the most significant impact areas for the long-term health outcomes of both infants and mothers. Madeline Sands and Elloise Foster from the young team of innovators at Small World Social will take you through this exciting trial. What worked, what didn’t and what were the unexpected surprises of using these new technologies?

The team used a range of research methods to inform their work and have developed a new and exciting approach to this very personal area. Speaker Bios

Madeline Sands as the Leader of the Breastfeeding Support Project and the Head of Data Visualization and Research, Madeline Sands is part of Small World Social’s founding team. Reflective of her millennial generation—well traveled, highly educated and rapidly changing the world through technology. With a background in mathematics and visual arts and known

as a talented storyteller, her love of technology will be sure to inspire. Madeline has been able to envisage how wearable technologies like Google Glass could be a perfect tool to assist with an age old, yet surprisingly difficult health issue—breastfeeding.

Elloise Foster, Marketing and Account Manager, is interested in technology applications that can provide support throughout people’s daily life. With a background in media and communication, Eloise’s expertise is in translating complex concepts into practical and easy to grasp actions. Similar to many of her millennial generation peers, she is well traveled

having studied in Europe after undertaking her undergraduate communications degree in Australia. Elloise’s is interested in applications of wearable technologies like Google Glass, for improving health and wellbeing whilst combining traditional strategies of community development and peer support.

******************************************************************** PBSS, Wednesday Afternoon, May 28, 2014 Topic: BCS system / Dissolution and Solid Form Technologies: Advances, Impact on Drug

Absorption, and Applications in Drug Development” Speakers: Gordon Amidon, Gregory Amidon (U Michigan), Larry Wigman (Genentech) Date and Time: Wednesday, May 28, 2014, 12:45 -5:30 pm Location: Crowne Plaza Hotel, Foster City, CA Registration fee (US$): Regular: $105; For vendor-show reps: $25; For unemployed: $20; Webcast: $250; For others, details available upon online login.

See details at http://www.caco-ca.org/aspx/homeSF.aspx as they are announced

************************************************************************* BioScience Forum, Wednesday Evening, May 28, 2014 Title: "Personalized Cancer Treatment and the Challenge of Acquired Drug Resistance" Speaker: Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech Date and Time: May 28th, 2014, 6:00 pm

6:00 PM - networking

7:00 PM - dinner

8:00 PM - presentation

Location: The Holiday Inn, 275 S. Airport Blvd, South San Franciso, CA 94080

8

Price: $45 before 9PM, Monday, May 27, $55 on-site; $35 full-time students pre-registration;

$45 full-time students on-site

$3 service fees will be added to the pre-registration prices

Details and registration at http://biosf.org/

Topic Description Drugs that target genetically-defined vulnerabilities in human tumors have been clinically validated as effective cancer therapies. In the novel treatment paradigm of “personalized cancer medicine”, patients are matched with the optimal drug regimen based on genomic features of their individual tumor. In many cases, these treatments produce remarkable clinical benefit, even in patients with advanced metastatic disease. However, relatively rapid acquisition of resistance to these drugs is observed in virtually all cases. This significantly limits their overall utility, and remains a substantial challenge to the clinical management of advanced cancers. As molecular mechanisms of drug resistance are elucidated, new strategies to overcome or prevent the development of resistance have emerged. In some cases, specific genetic selection mechanisms contribute directly to acquired drug resistance. In others, it appears

that non-mutational, possibly “epigenetic”, mechanisms play a significant role. Second-generation drugs, or combination drug treatment strategies, appear to provide a path toward addressing the challenge of drug resistance. Various reported genetic and non-genetic mechanisms of acquired drug resistance, as well as strategies to overcome these

resistance mechanisms, will be discussed in the context of “rationally-targeted” drug therapies. Speaker Bio Dr. Settleman received his B.A. in Neuroscience from the University of Pennsylvania in 1983, and a Ph.D. degree in Genetics from Yale University in 1989. He did his post-doctoral training at M.I.T. Dr. Settleman’s research is focused on cancer biology and therapeutics. He joined the Harvard School of Medicine faculty in 1992, and was named the Laurel Schwartz Professor of Oncology at Harvard Medical School in 2008. He was also the Director of the Center for Molecular Therapeutics and the Scientific Director of the Massachusetts General Hospital Cancer Center. In 2010, Dr. Settleman joined Genentech, where he is currently the Senior Director of Discovery Oncology, overseeing efforts to identify and validate targets for oncology drug discovery and to discover predictive biomarkers for new cancer therapies. His is particularly interested in personalized cancer medicine and mechanisms of drug resistance, and has authored more than 200 scientific publications. ************************************************************************* CABS, Wednesday, May 28, 2014 Event: “CABS Business & Career Development Workshop- Job Search and Interview Workshop” Moderators: Dr. Kai Zheng and Dr. Sean Wu; Speakers: Dr. Melisa S. Medrano, Staffing Consultant, Gilead Sciences, Inc.; Ms. Katherine Yagel, Director of Professional Services, Lee Hecht Harrison (LHH); Mr. Howard Simon, J.D., Chief Operating Officer & General Counsel, DNA2.0; Dr. Leping Li, Vice President of Chemistry, Presidio Pharmaceuticals; Mr. Don Lim, Sr. Recruiter, Yahoo and previously at Onyx

9

Date and Time: Date : Wednesday, May 28th, 2014, 5:30 - 8:30 pm 5:30 - 6:00 pm Check in & on-site registration 6:00 - 6:10 pm Speaker introduction 6:10 - 6:40 pm Job search and interview strategy overview

6:40 - 7:40 pm Panel discussion & Q/A 7:40 - 8:30 pm Networking Location: Room M106, Always Building, School of Medicine, Stanford University

Registration fee:

Online CABS/CBA member - $5, non-member - $10 Onsite CABS/CBA member - $10, non-member - $15 On-line registration will be closed by May 25th, 2014 (it will close sooner if the seating cap is reached)

Pizza and soft drinks will be provided. Topic Description Job search could be a long and stressful process and a job interview is one of the most drawn-out and intimidating ways of making first impression. The way you behave in your

first interview will be highly important in getting your desired job. However, it's also your opportunity to get on an employer's good side, which can give you a distinct edge over even those applicants whose credentials are better than yours. In this special event, experienced recruiters and industry elites will share with their valuable advice and experience to help

you succeed in your job search and interview and start your career in biopharmaceutic industry. Speaker Bios

Dr. Melisa S. Medrano Title: Staffing Consultant, Gilead Sciences, Inc. Dr. Medrano obtained her PhD in Molecular Biology and Microbiology from the Tufts University Sackler School of Biomedical Sciences in Boston, studying bacterial pathogenesis

in Borrelia burgdorferi, the causative agent of Lyme disease. After graduate school, Dr. Medrano transitioned into scientific recruiting. Dr. Medrano worked for Kelly Scientific Resources for a total of 5 years, first as a Scientific recruiter in Boston, and then in the Bay Area, where she supported companies from biotech and pharma to biofuels. In July of

2013, Dr. Medrano moved into an on-site recruiting role with Gilead Sciences, a global Biopharmaceutical company based in Foster City. Dr. Medrano staffs primarily for the Biologics Clinical Development/Production facility in Oceanside, but have also supported a

10

number of opportunities here at the Foster City site. Dr. Medrano enjoys recruiting and the ability to apply her scientific background to work with both hiring managers and candidates. Ms. Katherine Yagel

Title: Director of Professional Services for Lee Hecht Harrison (LHH) Ms. Yagel joined LHH following several years in independent practice in leadership coaching and career development for technical high-performers in organizations including Agilent Technologies, Cisco Systems, Genentech, Hewlett Packard Labs, and Juniper Networks. Ms. Yagel's background includes over 15 years in high- and bio-technology focused on

domestic and international marketing, business development, training (technical and management), and operation's project management at Apple, MIRC, GeneticXchange, United Bank of Denver, and others. With experience in Fortune 500 and start-ups, Ms. Yagel has participated in raising seed and continued-round funding and presented to Boards of

Directors. Ms. Yagel holds both a BA and MA in Psychology, with an emphasis in neuroscience, and an MBA from Cambridge University, UK specializing in international management and organizational development.

Dr. Leping Li Title: Vice President of Chemistry at Presidio Pharmaceuticals. Prior to joining Presidio, Leping was a Scientific Director at Amgen and held positions at

Tularik before its acquisition by Amgen. He was with the pharmaceutical division of Abbott Laboratories during the 1990s. During his 20+ years in the pharma/biotech industry, he has led project teams and advanced multiple programs from early lead identification to clinical development across several therapeutic areas, including infectious diseases, cancers and

metabolic disorders. Dr. Li obtained his BS degree in Chemistry from Shandong University in China. As a recipient of a China-US exchange scholarship (the Chemistry Graduate Program), he attended Rice University earning his Ph.D. degree in Organic Chemistry. Dr. Li also conducted postdoctoral research at Stanford University.

******************************************************************** CABS and Orrick, Thursday Evening, May, 29, 2014 Topic: “What Chinese American Professionals Should Know About Trade Secrets and Export Control Cases: Lessons from Civil Lawsuits and Criminal Prosecutions” Speakers: Zheng (Jen) Liu, Of Counsel Orrick, Herrington & Sutcliffe; Warrington Parker, Partner Orrick, Herrington& Sutcliffe; Eugene Illovsky, Parter Morrison Foerster Date: Thursday, May 29, 2014; 6:30 pm - 8:30 pm Location: Orrick Silicon Valley, 1100 Marsh Road, Menlo Park, CA 94025 Refreshments will be served. Register on line at http://reaction.orrick.com/reaction/RSGenPage.asp?RSID=PGa0Bp41gTKNCYCEIbbaFBNehAaUacDwfbKsF-jGk7Y Topic Description When a trade secrets case in the U.S. involves a foreign country, more than 60% of the time that foreign country is China. Among the significant criminal trade secrets cases prosecuted by the U.S. Department of Justice (DOJ), more than 80% involve Chinese defendant(s). Among the significant criminal export control cases prosecuted by DOJ, more than one-third is against Chinese defendant(s). Moreover, on average, Chinese defendant(s) get longer sentences. Eli Lilly, Pittsburgh Corning Corp., Motorola, Toray Industries, and DuPont Co. are just several companies whose Chinese employees faced high-profile trade secrets or export control criminal prosecution, some of which took place in

11

the Bay Area. There are many lessons we can learn from those cases that can prevent us from inadvertently making mistakes that may violate trade secrets law and export control regulations. Please join us for our evening program, co-organized by CABS and Orrick Herrington &

Sutcliffe, which will include expert speakers discussing trade secrets law, export control regulations and how to avoid making that may be costly financially and personally. *********************************************************************** Golden Gate Polymer Forum Dinner Lecture, Monday Evening, June 2, 2014

Discounted Advance Registration ends 11:59 PM, Tuesday, May 27 Final registration ends 5pm Sunday, June 1. Register at www.GGPF.org Topic: “One-micon-thick Organic Electronics: Going Thin for Ultraflexible, Stretchable, and Scalable Biomedical Sensors" Speaker: Prof. Tsuyoshi Sekitani, Osaka University, Japan Date and Time: Monday, June 2, 2014, 6:00 pm 6:00 PM social hour 7:00 PM dinner 8:00 PM presentation Location: Crowne Plaza Hotel, 4290 El Camino Real, Palo Alto, CA Cost: Employed/postdocs: $30 early registration, $35 regular registration Unemployed/retired/students: $15 early registration, $20 regular registration Free if you attend just the lectures at 8:00 PM (but please let us know for headcount) After deadline: Registration not guaranteed, so contact us Late fee applies if space available -- $40 regular/employed, $25 unemployed/student/retired GGPF Registration timelines and pricing policy. There is a discount for early registration in addition to a penalty for late registration. See the table below. This is effective for all monthly dinner lectures. Registration may close earlier than the nominal deadline if capacity is reached. Deadlines for registration: End of Discounted Advance Registration: Tuesday, May 27, 11:59 PM End of regular (full-price) registration: Sunday, June 1, 5 PM Because we must pay the restaurant for the ordered meal, we must ask no-shows to pay for their reservation. However, penalty-free cancellations are allowed up until the deadline for reservations the day before the event. PLEASE NOTE: We accept cash or checks at the door, but are unable to accept payment by credit card at the event. You may pay at the door. Checks may be made to "GGPF" Please register on the web page Or, if necessary, contact: Claudia Allison callison@delphon.com 510-576-2234 Topic Description

12

This talk will provide a review of our latest work in the area of large-area, ultraflexible, stretchable electronics. Our work focused on 1-micron-thick ultra-flexible, -thin and -lightweight organic electronics for next-generation wearable electronics, biomedical sensors, and intelligent welfare. Ultraflexible, stretchable electronics are a recent branch of electronics mainly driven by research on organic materials, device physics, and process engineering by the manufacture of thin-film transistors (TFTs), light-emitting diodes (LEDs), and photodetectors (PDs) on polymeric plastic substrates. On the basis of our initial work on manufacturing flexible organic circuits including TFTs, LEDs, and PDs, we developed organic flexible electronics with application to large-area sensors and actuators [1-7]. Recently, ultraflexible and lightweight electronics are manufactured on 1-micron-thick plastic substrates [8-11]. These devices are over ten times thinner, lighter, and more flexible than electronics of any technology to date. For example, by taking advantage of an ultraflexible and compliant amplifier that can amplify biological signals by 500, we developed 64-channel active matrix electrocardiogram and electromyogram monitoring systems. Ultrathin electronics with a total thickness of approximately 1–2 µm allow bending to a radius of less than 10 µm. Such foils can be even crumpled without electronic failure, paving the way for imperceptible electronics. The final part of the talk will comprise issues considered to be bottlenecks, delaying future advances, and the future prospects for these electronics will be discussed. This talk will demonstrate the promising future of organic electronics for the next generation of biomedical applications, offering scientific curiosity and real-world applications. Speaker Bio Tsuyoshi Sekitani received his M.S. and Ph.D. from the Department of Applied Physics, School of Engineering, the University of Tokyo, Japan, in 2001 and 2003, respectively. From 2003 to 2010, he was an Assistant Professor in the Department of Applied Physics at the University of Tokyo. In 2011, he was an Associate Professor in the School of Engineering at the University of Tokyo. In 2014, he advanced to the role of Professor in The Institute of Scientific and Industrial Research at Osaka University. His current research interests include organic transistors, flexible electronics, plastic integrated circuits, large-area sensors, and plastic actuators. He has received several awards, including the 2009 and 2010 Paul Rappaport Award for the best paper in the 2009 and 2010 IEEE Transactions on Electron Devices.

***********************************************************************

Janssen Labs, Wednesday and Thursday, June 4-5, 2014 Topic: “Meet with Wellcome” Date and Time: Wednesday and Thursday, June 4-5, 2014, 10:30 AM to 12:30 PM (PDT) Wednesday June 4, 2014

10:30am | Registration and Networking 11:00am | Presentation and Q&A 11:30am | Networking Lunch 12:30-5:00pm | One-on-one Meetings*

Thursday June 5, 2014 1:00-5:00pm | One-on-one Meetings*

13

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends April 25, 2014. APPLY HERE

Location: Stanford Park Hotel, Menlo Room, 100 El Camino Real, Menlo Park, CA 94025 Register at http://www.eventbrite.com/e/meet-with-wellcome-trust-tickets-10815997941?aff=blast Cost: General public $30; onsite $40 Wellcome Trust Participating Representatives: Keith Spencer, PhD | Business Development Analyst, Wellcome Trust read bio» Tim Jinks, PhD | Senior Business Analyst, Wellcome Trust read bio» Fees: Presentation & Lunch Only $30 | General Public

$40 | General Public Onsite Includes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until June 3rd.

One-on-One Meeting It is free to apply, but upon acceptance the following fees will apply: $25 | Accepted Companies Includes one-on-one meeting only. Companies must have applied for a one-on-one meeting

ahead of time. The application period ends on Friday, April 25. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. Wellcome Trust Representatives' Biographies:

Keith Spencer, PhD | Business Development Analyst, Wellcome Trust Keith joined the Trust in 2011. Previously, he worked for Arrow Therapeutics as a Group Leader for anti-infective drug discovery.During his nine year tenure at Arrow, Keith was project leader for multiple programs resulting in the discovery of two clinical candidates for hepatitis C. Keith holds a DPhil in organic chemistry from Oxford University, where he worked under the supervision of Professor Sir Jack E. Baldwin. He subsequently worked as a postdoc at the University of Pennsylvania in Philadelphia. Keith also holds a MChem in Chemistry from the University of St Andrews.

Tim Jinks, PhD | Senior Business Analyst, Wellcome Trust Tim has over a decade of industry experience most recently as a consultant providing business development, licensing and commercial research services.Previously he was a Business Development executive at BTG International working on licensing and IP

development.His industry experience started as senior scientist with Iclectus Ltd, a spin-out company from the MRC Laboratory of Molecular Biology, Cambridge that developed an antibody engineering platform.He trained as a professional chemist at the University of Georgia before gaining his MA and PHD in Molecular Biology at Princeton University.

*************************************************************** Rosenman Institute, Wednesday Afternoon, June 4, 2014 Topic: “Empowering the Next Generation of Medical Innovators”

Date and Time: Wednesday, June 4th, 1:00 – 5:30 pm Registration & Networking Welcome: Reg Kelly, PhD, Director, QB3

Kathy Giacomini, PhD, Chair, UCSF Department of Bioengineering and Therapeutic Sciences Hanmin Lee, MD, Surgeon in Chief, UCSF Benioff Children's Hospital San Francisco Panel Discussion: "From Ideas to Commercialization: Lessons Learned"

14

The Rosenman Fellows Moderated by Reg Kelly "The Innovator's Dilemma in Surgery," Ken Drazan, MD, Head, Johnson & Johnson Innovation Center in California

"The Radically Changing Landscape for Medical Technology Innovation," Paul Yock, MD, Director, Biodesign, Stanford University Panel Discussion: "Insights on Early Stage Funding" Ned Scheetz, Managing Director, Aphelion Capital Allan May, Chairman & Founder, Life Science Angels

Moderated by Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati "So You Want to Be an Entrepreneur?," Frank Litvack, MD, serial entrepreneur Reception & Networking Location: Byers Auditorium, Genentech Hall, UCSF Mission Bay

For full details go to http://www.eventbrite.com/e/rosenman-institute-launch-symposium-empowering-the-next-generation-of-medical-innovators-tickets-11174484183 Symposium Description

The route for taking a medical device from idea to product generally isn’t smooth. Surgeons know what problems they need solved, but they often know little about bioengineering. Engineers are great at building products, but often don't know whether a device is needed

or wanted in the clinic. That’s why we created the Rosenman Institute, a UCSF-based initiative devoted to medical device innovation. The Institute, named for the late Dan Rosenman, a biomedical engineer,

is a collaboration between QB3, the UCSF Department of Surgery, the UCSF Department of Bioengineering, and medical device professionals. Our goal is to connect physician innovators with engineering expertise and business support to accelerate medical device innovation.

This symposium will inspire clinicians to innovate; introduce the resources available at the Rosenman Institute; and enable entrepreneurs to share their stories and their perspectives on the future of medical device innovation. It will also provide an opportunity for networking with entrepreneurs, physicians, investors, biomedical engineers, mentors and

representatives of major device companies. *******************************************************************

Life Science Investor Pitch Program, Thursday Evening, June 5, 2014 Event: “Life Sciences Investor Pitch” Moderator: Meredith L. Warshaw, PhD

Panelists: Alex de Winter, GE Ventures Wende Hutton, Canaan Partners June Fallon from Sand Hill Angels

Ben Pensak, Morgan Lewis Date and Time: June 5, 2014 | 6:00-8:30 PM Doors open and networking: 6 PM Program: 6:30-8:30 PM Hors d'oeuvres and beverages will be served.

Location: Morgan, Lewis & Bockius, LLP, Two Palo Alto Square, Palo Alto Agenda:

15

Registration: $45 VC Taskforce Members, $55 Affiliate Organization Member $75 General

Please note: Space is limited, register early! If you would like to pitch use this link: Register to pitch at https://www.eventbrite.com/e/life-sciences-investor-pitch-registration-to-pitch-tickets-11239881789

If you would like to be on "pitch stand-by" or in general attendance use this link: Register for general attendance and pitch standby at https://www.eventbrite.com/e/life-sciences-investor-pitch-stand-by-and-general-admission-tickets-11241141557

If you would like to pitch use this link: Register to pitch If you would like to be on "pitch stand-by" or in general attendance use this link:

Register for general attendance and pitch standby Topic Description The Life Science Investor Pitch programs through VC Taskforce offer an opportunity for

entrepreneurs seeking start up funding to pitch in front of a distinguished panel of investors. VC Taskforce and Morgan, Lewis & Bockius, LLP have partnered to bring to you a scintillating program series to bring entrepreneurs and investors together in the life science fields. The evening will be exciting and a terrific learning experience for all entrepreneurs.

Entrepreneurs learn what investors are looking for in a pitch presentation. Entrepreneurs seeking capital will pitch for 2 minutes in front of the investor panel. This is followed by 5 minutes of Q&A and then non-rebuttal feedback by the panel. A score of 1-5 is given to each presenting company by each panel member. Please note that pitching time

limits will be strictly enforced! Investors come and listen to entrepreneurs’ pitches. You never know where you’ll find your next deal. Find out how our panel of investors rates entrepreneurs’ pitches; which investors

pass and for what reasons; and which entrepreneurs other investors want to talk to ASAP. Please let us know if you would like to participate on one of our Life Science Investor Pitch panels.

This is a great opportunity for entrepreneurs to network with investors, present their company, and hear first-hand what it takes to raise early-stage capital. If you are an entrepreneur in a startup that is currently seeking capital and would like to present your best 2 minute elevator pitch to a panel of investors, you must register in advance and have

confirmation from the program manager that you are on the list of presenters. The maximum number of presenters is limited to ten. To present a pitch, prior to registering, please contact Maya Desai PhD,

mayudi80@gmail.com, or call 909.565.7201 to learn of slot availability. Slots to present are assigned on a first-come basis. If a slot is available you must register and send Maya Desai PhD your confirmation number and the name of your company. Receipt of your confirmation number ensures assignment of a presentation slot. You will also receive further instructions and advice on preparing your best pitch.

16

Please note: Registering does not reserve a pitch time. You must contact Maya Desai PhD per instructions above to reserve a slot to pitch.

ATTENDEE AUDIO OR VIDEO TAPING THIS PROGRAM IN WHOLE OR IN PART IS STRICTLY PROHIBITED. Life Science Chairperson: Meredith L. Warshaw, PhD mlwarshaw@gmail.com Program Manager: Maya Desai PhD

************************************************************** BayBio Pub Night, Thursday Evening, June 5, 2014 Event: “BayBio Pub Night”

Date and Time: Thursday, June 5, 2014, 5:30-7:30 Location: MeMe’s, 760 2nd Street, San Francisco No fee and no need to register. First drink free to bioscience with business card. Specialty cocktails and free appetizers

available.

Join your friends and colleagues at BayBio’s Life Science Pub Night. Come to MeMe’s in Redwood City on April 17th

from 5:30 to 7:30pm.

Bring your bioscience business card for 1 free drink!

************************************************************************

Bio2Device Group, Tuesday Evening, June 10, 2014 Topic: Critical Issues in International Women’s Health Speaker: Anne Firth Murray, International Women's Health

Date and Time: Tuesday Evening, June 10, 2014, 6:00 pm Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA Cost: $6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Register at Bio2Device Group website a week prior to event

Topic Description Anne will discuss issues of women's health, focussing on those that mean life or death to women depending on whether or not they can exercise their human rights; information and examples of positive interventions will be drawn primarily from the situations of poorer women in poorer countries. Short Bio: Anne Firth Murray, a New Zealander, teaches on international women’s health and human rights and on love as a force for social justice at Stanford University. She directed the environment and population programs of the Hewlett Foundation from 1978 to 1988. She is the Founding President of The Global Fund for Women, and directed it from 1987 to 1996. She serves on boards and councils of many groups, including the African Women’s Development Fund, CIVICUS, Global Force for Healing, and Grass Roots Alliance for Community Education. She has received awards and honors for women’s health and philanthropy, and in 2005 was nominated as one of a group of women for the Nobel Peace Prize. Her book on the early Global Fund for Women is Paradigm Found: Leading and Managing for Positive Change. Her other book, From Outrage to Courage: The Unjust and Unhealthy Situation of Women in Poorer Countries and What They Are Doing About It, is in 2nd edition.

17

Speaker Bio Anne Firth Murray is a New Zealand author, professor, and nonprofit founder. Murray is the founding president of the Global Fund for Women, the largest non-profit organization in the world funding women's human rights. She founded the organization in 1987 and continued

to act as president until 1996. In 2005, she was nominated for the Nobel Peace Prize. Anne Firth Murray previously led philanthropic efforts on population and environmental issues for the William and Flora Hewlett Foundation from 1978 to 1987. Prior to that she was a writer at the United Nations and an editor at the Oxford University Press, Stanford University Press, and Yale University Press.

Murray is the author of two books: Paradigm Found: Leading and Managing for Positive Change and From Outrage to Courage: Women Taking Action for Health and Justice. She is a consulting professor of International Women's Health at Stanford University. She is a board member or advisor to several organizations, including the African Women's

Development Fund and the Global Justice Center.

*****************************************************************************

PBSS, Friday Afternoon June 13, 2014 Topic: “Transporter ITC update: latest development in transporter science” Speakers: Kathy Giacomini (UCSF), Xiaoyang Chu (Merck), Maciej Zamek-Gliszczynski

(Lilly) Date and Time: Friday, June 13, 2014, 12:45 pm – 5:30 pm Location: Crowne Plaza Hotel, Foster City, CA Registration fee (US$): Regular: $105; For vendor-show reps: $25; For unemployed: $20; For others,

details available upon online login. Registration: http://www.PBSS.org

***************************************************************** Bio2Device Group, Tuesday Morning, June 17, 2014 Topic: TBA Speaker: Susan Rowinski, Rowinski Group

Date and Time: Tuesday, May 27, 2014, 8:30 am

Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA Cost: No fee and no need to register for morning meetings ******************************************************************************************

UC Berkeley Extension Course, Thursday and Friday, June 19-20, 2014 Course: “Life Science Business Development,” (formerly known as Biotechnology Business Development)

Dates and Time: Thursday and Friday, June 19-20; 8:30 am – 5:00 pm for classroom intensive and balance of term for working on term project Location: Downtown University of California, Berkeley Extension, 425 Market St., 8th Floor, San Francisco, CA 94105

Cost: Summer term—fee: $895, (440.8-001). Registration is open at http://tinyurl.com/mao7hjh

Course Description

This intensive course including two days of classroom and balance of term for individual research is designed to provide participants with an understanding of the critical role business development and licensing functions play in the commercialization of new products

18

or technology and to the development of a successful life science company. The term assignment is designed to give students the opportunity to put the knowledge and materials from class to immediate and practical use with resulting document for inclusion in their portfolio.

Upon successful completion of the course, participants will: Understand the various aspects of the business development function in the life science

industry and appreciate the skills required to be effective in business development and licensing roles

Appreciate types of deals and their role in commercialization strategies and funding of a

company Understand importance of IP status and patent life cycle planning Appreciate the role of pricing and reimbursement in the commercial assessment of life

science innovations that underlie deal valuations

Who Will Benefit from This Course This course is suitable for marketing and business development professionals as well as scientific professionals working in bioscience companies, especially those considering a

career move into BD. Licensing, potential entrepreneurs, scientific, clinical, regulatory financial, legal and auxiliary personnel will also benefit from insights gained in the course. Although there are no format prerequisites, those who have been exposed to the life science industry and/or the Drug Development Process course will most benefit from the course.

Deliverables Lectures, discussion, and guest expert lecturers will address business development topics and issues. Student will be exposed to templates and primers for major business

development documents and offered mentoring by instructor in researching and developing their term project. They will have access to two major industry databases for use in researching their project during the term. These include Deloitte’s Basic Recap.com, a life science deal database, and BioCentury’s Report on BioBusiness and access to latter’s archives.

An extensive hard-copy reader, including lecture slides for note-taking, templates for frequently-used business development documents and a sizable online accessible reference list, will be prepared and distributed by the instructor for use by students during and after class.

Course Instructor Audrey Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.com, is a life-science business development and marketing consultant and developer of

customized executive education. With more than 30 years of managerial experience in the biotech and pharmaceutical industry, she was Executive Vice President and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan and before that held U.S. and global

management positions at Syntex Corp. (acquired by Roche) in market research, product management, strategic marketing and planning, and business development. Guest Speakers and Their Topics

Jessica L. Holmes, Director of Reimbursement for Argenta Advisors, has 20 years of experience in payer relations, government affairs, reimbursement strategy and tactical planning. She has worked for manufacturers in home infusion therapy, medical device, biotechnology, capital equipment and diagnostics. Jessica provides expertise in analyzing

challenges and opportunities for market access in not only the traditional reimbursement environment of Medicare and commercial health plans, but in the evolving landscape of risk-

19

sharing/gain-sharing programs (e.g., ACOs) and pay-for-performance initiatives. Jessica uses her Degree in Mass Communications from UC Berkeley and her work in public relations to cross-functionally align reimbursement goals with corporate sales/marketing initiatives. Topic: “Developing and Positioning Technology in the Evolving Healthcare Reimbursement

Landscape” Harold (Hal) Etterman, MBA, CEO, Knight Financial Plans & Services, LLC has over twenty-five years experience in Finance, Operations and Information Technology, including over ten years serving as a CFO, COO and interim CEO. Hal’s extensive international and

domestic experience includes medial devices, software development, medical information publishing, Internet/data security and Homeland security systems. Hal had earlier worked for Siemens Medical Systems for nearly 17 years in Manufacturing Operations, Divisional Sales and Service, Corporate Finance and Information Systems. After Siemens, Hal was the

CFO/COO for a medical laser manufacturer and has served as a financial planning consultant for 3 medical device businesses. Most recently he has just completed four major Sarbanes-Oxley projects where he successfully helped his client firms through their internal audits resulting in SOX certified SEC filings. Topic: “Financial Planning and Funding for a Bioscience

Venture: New, Emerging and Growing Entities” Carolyn Feamster, MBA, a business strategy and analysis consultant, has over 25 years experience in the pharmaceutical and biotech therapeutics, diagnostics and drug delivery

systems. She has broad expertise across numerous therapeutic areas, including oncology, CNS, transplantation, autoimmune disease, women’s health and urology. Carolyn worked in R&D and pharmaceutical marketing at Syntex, where her responsibilities included the major brands Naprosyn and Cellcept. In 1995, Carolyn joined ALZA Corporation as Senior Director

of New Product Marketing with commercial responsibility for building and managing the pipeline products. She shepherded three products onto the market and was instrumental in evolving the three ALZA therapeutic franchises: urology, CNS and oncology. Carolyn was VP of New Product Planning at Corixa Corporation and, most recently, Vice President of Business Strategy and Analysis at Clearview Projects. Topic: "Preparing for and Planning

Deals for Maximum Strategic Impact" Gilbert R. Mintz, Ph.D., President of GRM Associates, a biotechnology business development, licensing, strategic planning consulting firm, has expertise in building early-

stage companies by focusing their strategic planning and licensing activities, and raising money through venture capitalists. His 20-plus years in the biotechnology industry include general and laboratory management and executive level business development roles. He has executed technology platform, corporate and academic collaborations; in/out licensing

of late-stage products for partnerships in the US, Europe and Japan; as well as analyzed and managed intellectual property activities. He has consulted with Affymetrix and other biotechnology companies; served as the President and CEO, Director of an early-stage cancer company; and provided transactional and strategic planning advice to numerous pre-

IPO biotechnology companies. He has held senior management positions at Genelabs Technologies, Anergen (Corixa), Cygnus and Trega Biosciences. Topic: “Working Your Way through the Bioscience Licensing Process: Negotiating and Writing Deal Contract”

Ginger Dreger, J.D., M.S., partner in Arnold & Porter LLP’s intellectual property practice group, concentrates her practice on counseling and providing strategic advice to emerging and established public companies in the biotechnology, medical device, and pharmaceutical industries. She advises clients on domestic and international patent matters, including worldwide patent protection and enforcement strategies; freedom-to-operate issues;

intellectual property due diligence; and analysis of third-party patents. Corporate

20

experience included role with Genentech’s in-house legal department. Topic: "What You Need to Know about Patents Working in Business Development"

Chris Dokomajilar serves as the Director of Business Intelligence at BioCentury where he is responsible for growth initiatives across biopharmaceutical deals and business information. Chris was previously at Recap at Thomson Reuters (formerly Deloitte Recap LLC and Recombinant Capital) as the Senior Deal Analyst managing a data and consulting group covering biopharmaceutical licensing, M&A, and financing. He enjoys the opportunity to

contribute to industry thought-leadership and is frequently invited to speak to trade and industry groups about business development, licensing, and commercialization.

Prior to joining Recap, Chris managed international labs and clinical research at the University of California San Francisco. His research on epidemiological trends in infectious diseases has been published in medical and scientific journals. Before transitioning into science, Chris served in finance positions of increasing responsibility at Bank of America. He holds bachelor’s degrees from the University of California Berkeley in Molecular and Cell Biology and in Integrative Biology. Topic: “BioPharma Alliances: Trends in the Marketplace”

Course Content Outline

The Function of Business Development In A Bioscience Company Financing The Development And Commercialization Process Of Life Science Products

And Technologies The Role of Pricing and Reimbursement in Life Science Dealmaking Preparing for and Planning Deals for Maximum Strategic Impact Developing And Protecting The Product’s Intellectual Property Status Licensing Process

**************************************************************** HealthTech Capital and Stanford Hospital, Tuesday and Wednesday, Oct. 14-15 Event: “ HealthTech Conference - Growing Your Business in the New Healthcare Ecosystem” Date: Tuesday and Wednesday, October 14 and 15, 2014 Location: San Mateo Event Center, Fiesta Hall, 1346 Saratoga Avenue (parking), San Mateo, CA Web: www.HealthTechConference.com Early Bird: $650 (normally $950)

Workshops: included in conference registration Register at https://www.eventbrite.com/e/healthtech-conference-2014-registration-10574437427 Conference Description HealthTech Capital and Stanford Hospital are proud to co-host the leading conference on building successful HealthTech companies. Our panels, presentations, and discussions are practical and in-depth. This year, both emerging and established companies are joining the conversation. All in the same room, you'll find a unique blend of payers, providers, investors, established corporations, and entrepreneurs. We are honored to have an unmatched lineup of stellar speakers and panelists, including:

Amir Dan Rubin, CEO; Stanford Hospital Chris Willrich, Regional VP of Strategy & BD, Sutter Health

21

Steve Myers, CTO, Optum Health Behavioral Solutions David Sayen, Regional Administrator, Centers for Medicare and Medicaid Services Jody Holtzman, Senior VP Thought Leadership, AARP Jack Young, Managing Director, Qualcomm Life Fund

Joel Krikston, Managing Director, Merck Global Health Innovation Fund Wende Hutton, Managing Director, Canaan Partners Nathan Gunn, MD, President of Population Health, Valence Health Pat Basu, CMO, Doctors on Demand Owen Tripp, CEO, GrandRounds Health

Bryan Roberts, Managing Director, Venrock Benefits of Attending

Learn from leaders and top executives on the panels Network with industry leaders, establish relationships with new companies, deepen

current customer relationships, and learn about challenges, priorities, and solutions Visit with established companies, and see emerging innovations and technologies.

*********************************************************************